Government Contracts
JULY 3, 2024
Department of Health and Human Services in Boehringer Ingelheim's challenge to a new Medicare drug price negotiation program, rejecting the pharmaceutical company's claim that the program is unconstitutional. A Connecticut federal judge on Wednesday sided with the U.S.
Government Contracts & Investigations
SEPTEMBER 25, 2023
Welcome back to the Cost Corner, where we provide practical insight into the complex cost and pricing requirements that apply to Government Contractors. We just completed two articles on the Truth in Negotiations Act (TINA) [1] and, before that, two articles on Defense Contract Audit Agency (DCAA) audits.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Government Contracts
JULY 29, 2024
notified a Connecticut federal court Friday that it will appeal its loss in a lawsuit challenging a new Medicare drug price negotiation program on the grounds that it unlawfully compels the pharmaceutical giant to declare prices "fair," takes its property and imposes an excessive fine. Boehringer Ingelheim Pharmaceuticals Inc.
Government Contracts
JUNE 20, 2024
An "unprecedented" new Medicare price negotiation program deprives drugmakers of their constitutional rights and forces them to make declarations on issues of public concern that reflect poorly on them, Boehringer Ingelheim Pharmaceuticals Inc.
Public Contracting Institute
MAY 9, 2024
Special focus on contract pricing). price negotiations and procedures should be used by contracting officers to determine the price reasonableness of modifications offered under a sealed bid contract. Contracting officers are required to document in the contract file the principal elements of the negotiated agreement.
Government Contracts
DECEMBER 21, 2023
Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to reject the company's claims of constitutional violations.
Government Contracts
DECEMBER 4, 2023
AstraZeneca has chided the federal government for seeking a quick win against the drugmaker's challenge to the Medicare drug price negotiation program in a recent brief, arguing that the Centers for Medicare and Medicaid Services mistakenly believes it has "absolute authority to unilaterally dictate prices."
Expert insights. Personalized for you.
98 
Let's personalize your content